American Association for Cancer Research
Browse
00085472can131528-sup-tab2.pdf (78.21 kB)

Supplementary Table 2 from A Circadian Clock Transcription Model for the Personalization of Cancer Chronotherapy

Download (78.21 kB)
journal contribution
posted on 2023-03-30, 22:14 authored by Xiao-Mei Li, Ali Mohammad-Djafari, Mircea Dumitru, Sandrine Dulong, Elisabeth Filipski, Sandrine Siffroi-Fernandez, Ali Mteyrek, Francesco Scaglione, Catherine Guettier, Franck Delaunay, Francis Lévi

PDF file - 78K, Plasma pharmacokinetic parameters (Mean plus/minus SEM) of irinotecan according to timing and chronotoxicity classes.

History

ARTICLE ABSTRACT

Circadian timing of anticancer medications has improved treatment tolerability and efficacy several fold, yet with intersubject variability. Using three C57BL/6-based mouse strains of both sexes, we identified three chronotoxicity classes with distinct circadian toxicity patterns of irinotecan, a topoisomerase I inhibitor active against colorectal cancer. Liver and colon circadian 24-hour expression patterns of clock genes Rev-erbα and Bmal1 best discriminated these chronotoxicity classes, among 27 transcriptional 24-hour time series, according to sparse linear discriminant analysis. An 8-hour phase advance was found both for Rev-erbα and Bmal1 mRNA expressions and for irinotecan chronotoxicity in clock-altered Per2m/m mice. The application of a maximum-a-posteriori Bayesian inference method identified a linear model based on Rev-erbα and Bmal1 circadian expressions that accurately predicted for optimal irinotecan timing. The assessment of the Rev-erbα and Bmal1 regulatory transcription loop in the molecular clock could critically improve the tolerability of chemotherapy through a mathematical model–based determination of host-specific optimal timing. Cancer Res; 73(24); 7176–88. ©2013 AACR.